Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.4K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.4K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.9K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.9K
Electrical Current01:10

Electrical Current

7.2K
Electrical current is defined as the rate at which charge flows. When there is a large current present, such as that used to run a refrigerator, a large amount of charge moves through the wire in a small amount of time. If the current is small, such as that used to operate a handheld calculator, a small amount of charge moves through the circuit over a long period of time. The SI unit for current is the ampere (A), named for the French physicist André-Marie Ampère (1775–1836).
7.2K
Current Density01:21

Current Density

5.2K
The total amount of current flowing through one unit value of a cross-sectional area is referred to as current density. If the current flow is uniform, the amount of current flowing through a conductor is the same at all points along the conductor, even if the conductor area varies. The current density consists of the local magnitude and direction of the charge flow, which varies from point to point. Current density is measured in amperes per meter square, and direction is defined as the net...
5.2K
Eddy Currents01:25

Eddy Currents

2.7K
Since eddy currents occur only in conductors, magnets can separate metals from other materials. For example, in a recycling center, trash is dumped in batches down a ramp, beneath which lies a powerful magnet. Conductors in the trash are slowed by eddy currents, while nonmetals in the trash move on, separating from the metals. This works for all metals, not just ferromagnetic ones.
Other major applications of eddy currents appear in metal detectors and the braking systems of trains and roller...
2.7K
Displacement Current01:19

Displacement Current

3.8K
Ampère's law, in its usual form, does not work in places where the current changes with time and is not steady. Thus, Maxwell suggested including an additional contribution, called the displacement current, Id, to the real conduction current I.
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Overview].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2026
Same author

Associating the phenotypic expression of platelets with disease type through image-based single-cell profiling.

Thrombosis research·2026
Same author

A Functional TNFRSF13B Variant Disrupts B-Cell Enhancer Activity and Increases Susceptibility to EBV-Negative Lymphoma.

Gene·2026
Same author

Global survey of women's awareness of pregnancy- and postpartum-associated venous thromboembolism (World Thrombosis Day 2025).

Research and practice in thrombosis and haemostasis·2026
Same author

Prolonged low-dose tPA ameliorates coagulopathy and organ injury in an LPS-induced rat DIC model.

International journal of hematology·2026
Same author

Real-time imaging of platelet dynamics in engineered arterial, venous, and cancer-associated thrombotic microenvironments.

Biofabrication·2025

Related Experiment Video

Updated: Feb 8, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.9K

[Anticoagulants: current topics].

Eriko Morishita1

  • 1Department of Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University.

[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|July 6, 2018
PubMed
Summary

New anticoagulants targeting factor XI are needed for venous thromboembolism (VTE) in cancer patients. Direct oral anticoagulants like edoxaban show promise, with specific reversal agents available for bleeding emergencies.

Keywords:
4-factor prothrombin complex concentrateDirect oral anticoagulants (DOAC)Factor XIIdarucizumab

More Related Videos

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Generation of Topically Transgenic Rats by In utero Electroporation and In vivo Bioluminescence Screening
08:44

Generation of Topically Transgenic Rats by In utero Electroporation and In vivo Bioluminescence Screening

Published on: September 24, 2013

14.5K

Related Experiment Videos

Last Updated: Feb 8, 2026

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood
07:08

Assessment of the Anticoagulant and Anti-inflammatory Properties of Endothelial Cells Using 3D Cell Culture and Non-anticoagulated Whole Blood

Published on: September 5, 2017

8.9K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.4K
Generation of Topically Transgenic Rats by In utero Electroporation and In vivo Bioluminescence Screening
08:44

Generation of Topically Transgenic Rats by In utero Electroporation and In vivo Bioluminescence Screening

Published on: September 24, 2013

14.5K

Area of Science:

  • Pharmacology and Thrombosis Research
  • Oncology and Anticoagulation

Background:

  • Current anticoagulants like heparin and warfarin have limitations, necessitating safer and more effective antithrombotic strategies.
  • The contact system, particularly factor XI, is identified as a potential target for novel anticoagulant therapies.
  • Venous thromboembolism (VTE) affects a significant portion of cancer patients, complicating their treatment.

Purpose of the Study:

  • To evaluate the efficacy and safety of direct oral anticoagulants (DOACs) in cancer patients with VTE.
  • To explore the potential of factor XI as a target for new anticoagulant development.
  • To discuss the importance of emergency neutralization strategies for anticoagulants.

Main Methods:

  • A large-scale international clinical trial assessed composite outcomes of VTE recurrence and major bleeding.
  • Comparison of edoxaban (a direct factor Xa inhibitor) versus low-molecular-weight heparin in cancer patients.
  • Review of existing and emerging anticoagulant reversal agents.

Main Results:

  • Edoxaban demonstrated non-inferiority to low-molecular-weight heparin in preventing VTE recurrence and major bleeding in cancer patients.
  • Direct oral anticoagulants (DOACs) show promising therapeutic potential in future studies.
  • Four-factor prothrombin complex concentrate and idarucizumab are discussed as effective reversal agents.

Conclusions:

  • Direct oral anticoagulants (DOACs) represent a viable therapeutic option for VTE in cancer patients.
  • Targeting factor XI offers a promising avenue for developing safer anticoagulants.
  • Availability of specific reversal agents enhances the safety profile of anticoagulant therapy.